TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15729173

Group type: EXPERIMENTAL
Intervention: Supplemental arginine and canola oil (omega-3 and omega-9 fatty acids) twice daily
Number of subjects: 147
Study: 12746761

Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Glibenclamide (GB)
Number of subjects: 143
Study: 11046211

Group type: EXPERIMENTAL
Intervention: HES200 (15 ml/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: HES70 (15 ml/kg)
Number of subjects: 22
Study: 9075745

Group type: EXPERIMENTAL
Intervention: Preoperative multimodality therapy (Group 1) including seven cycles of 5-fluorouracil (FU)/leucovorin (LV) chemotherapy and radiation therapy (5,040 cGy) before surgery.
Number of subjects: 116

Group type: COMPARATOR
Intervention: Postoperative multimodality therapy (Group 2) including the same chemotherapy and radiation therapy after surgery.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Preoperative multimodality therapy (Group 1).
Number of subjects: 116

Group type: COMPARATOR
Intervention: Postoperative multimodality therapy (Group 2).
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2).
Number of subjects: 116
Study: 8422745

Group type: EXPERIMENTAL
Intervention: Fenoterol metered dose inhaler (0.4 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fenoterol dry powder capsules (0.4 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Colforsin dry powder capsules (10.0 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3024826

Group type: EXPERIMENTAL
Intervention: BTOC (carmustine, thiotepa, vincristine, and cyclophosphamide)
Number of subjects: 428

Group type: COMPARATOR
Intervention: CAV (cyclophosphamide, doxorubicin, and vincristine)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: BTOC followed by multiple-site irradiation
Number of subjects: 428

Group type: COMPARATOR
Intervention: CAV followed by multiple-site irradiation
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Multiple-field irradiation consolidation
Number of subjects: 428
Study: 30913065

Group type: EXPERIMENTAL
Intervention: Visual-spatial neglect (VSN) group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Non-VSN group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: VSN group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: VSN group and Non-VSN group
Number of subjects: 33
Study: 28391875

Group type: EXPERIMENTAL
Intervention: MAT9001
Number of subjects: 42

Group type: COMPARATOR
Intervention: EPA-EE
Number of subjects: 42
Study: 26200232

Group type: EXPERIMENTAL
Intervention: Blood transfusion protocol
Number of subjects: 2016
Study: 23470806

Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol (cilo)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aspirin alone (non-cilo group)
Number of subjects: 20
Study: 21946218

Group type: EXPERIMENTAL
Intervention: Single site umbilical laparoscopic appendectomy
Number of subjects: 360

Group type: COMPARATOR
Intervention: Standard 3-port laparoscopic appendectomy
Number of subjects: 360
Study: 19111610

Group type: EXPERIMENTAL
Intervention: Antioxidant (AO) supplementation (200 IU of vitamin E and 500 mg ascorbic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study: 16641947

Group type: EXPERIMENTAL
Intervention: Neurocognitive tests administered (11 tests resulting in 24 individual scores)
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Single-factor model comprised of five domain scores
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Correlation with negative symptom severity
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Correlation with positive symptom severity
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Composite score derived from individual factors
Number of subjects: 1493
Study: 15448595

Group type: EXPERIMENTAL
Intervention: Anterior approach
Number of subjects: 59

Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 59
Study: 11399983

Group type: EXPERIMENTAL
Intervention: Amprenavir (APV) 450 mg with Ritonavir (RTV) 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amprenavir (APV) 450 mg with Ritonavir (RTV) 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amprenavir (APV) 900 mg with Ritonavir (RTV) 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ritonavir (RTV) co-administration with APV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) 100 mg
Number of subjects: 0
Study: 9757514

Group type: EXPERIMENTAL
Intervention: Hop-valerian preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzodiazepine preparation
Number of subjects: 0
Study: 7914050

Group type: EXPERIMENTAL
Intervention: Haloperidol (2, 4 and 6 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remoxipride (100 and 150 mg)
Number of subjects: 0
Study: 2905152

Group type: EXPERIMENTAL
Intervention: levocabastine (200 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: saline
Number of subjects: 10
Study: 28513238

Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Knowledge and understanding of physical exercise
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Involvement of staff and family carers
Number of subjects: 19
Study: 28187725

Group type: EXPERIMENTAL
Intervention: Web-based cancer aftercare intervention for 6 months
Number of subjects: 462

Group type: COMPARATOR
Intervention: Control group (access after 12 months)
Number of subjects: 462
Study: 26189601

Group type: EXPERIMENTAL
Intervention: Shorter sleep duration
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Food responsiveness (FR) mediation
Number of subjects: 1008
Study: 23458045

Group type: EXPERIMENTAL
Intervention: Outpatient haemorrhoidectomy
Number of subjects: 208

Group type: COMPARATOR
Intervention: Inpatient haemorrhoidectomy
Number of subjects: 208
Study: 21296010

Group type: EXPERIMENTAL
Intervention: Televideoconferencing (TVC)
Number of subjects: 78
Study: 19426757

Group type: EXPERIMENTAL
Intervention: Supported home-based walking during the 12-week RCT
Number of subjects: 38
Study: 16989189

Group type: EXPERIMENTAL
Intervention: 633-nm and 830-nm LED treatments
Number of subjects: 36
Study: 15259281

Group type: EXPERIMENTAL
Intervention: 500 mg/day of tricalcium phosphate (TCP)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 500 mg/day of ossein‐hydroxyapatite (OHC)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 11199708

Group type: EXPERIMENTAL
Intervention: Thermafil
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lateral condensation
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: McSpadden
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 160
Study: 9264275

Group type: EXPERIMENTAL
Intervention: High vegetable, low fat diet intervention
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study: 8570762

Group type: EXPERIMENTAL
Intervention: Brofaromine (selective and reversible inhibitor of monoamine oxidase type A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine (standard tricyclic compound)
Number of subjects: 0
Study: 10148140

Group type: EXPERIMENTAL
Intervention: Dextranomer paste (Debrisan)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Polyvinylpyrrolidone (control)
Number of subjects: 40
Study: 105442

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapeutic agents
Number of subjects: 0
Study: 31872213

Group type: EXPERIMENTAL
Intervention: Genetically predicted HDL-C (per standard deviation increase)
Number of subjects: 181677

Group type: EXPERIMENTAL
Intervention: Genetically predicted triglycerides
Number of subjects: 181677

Group type: EXPERIMENTAL
Intervention: Genetically predicted total cholesterol
Number of subjects: 181677

Group type: EXPERIMENTAL
Intervention: Genetically predicted LDL-C
Number of subjects: 181677
Study: 29354921

Group type: EXPERIMENTAL
Intervention: Scraping therapy (4 sessions over 4 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Scraping therapy (lung qi deficiency and cold group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cetirizine (10 mg, once a day for 4 weeks)
Number of subjects: 80
Study: 25601933

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 6 months
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: CPAP treatment (per-protocol analysis)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (per-protocol analysis)
Number of subjects: 117
Study: 25401208

Group type: EXPERIMENTAL
Intervention: Music-focused relaxation group (38 subjects)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Music and video group (35 subjects)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (39 subjects)
Number of subjects: 112
Study: 22447547

Group type: EXPERIMENTAL
Intervention: TISSEEL (fibrin glue)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Vicryl 8‐0 sutures
Number of subjects: 43
Study: 20711439

Group type: EXPERIMENTAL
Intervention: Superficial heat therapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cold therapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Contrast therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Heating pad (control)
Number of subjects: 34
Study: 17394940

Group type: EXPERIMENTAL
Intervention: Zinc sulfate 45 mg orally three times daily
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 16287453

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily for 2 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 12011810

Group type: EXPERIMENTAL
Intervention: Telephone intervention by nurses providing information and support, 6 calls over 7 weeks
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 131
Study: 10027102

Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ceftazidime
Number of subjects: 37

Group type: COMPARATOR
Intervention: ceftriaxone + aminoglycoside
Number of subjects: 37
Study: 8907444

Group type: EXPERIMENTAL
Intervention: Wheeled walking aid
Number of subjects: 11
Study: 1872346

Group type: EXPERIMENTAL
Intervention: Psychosocial support between enrollment at +/‐ 20 weeks and delivery at +/‐ 38 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard care at the antenatal clinic
Number of subjects: 86
Study: 6214234

Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zimelidine hydrochloride
Number of subjects: 12
Study: 29902061

Group type: EXPERIMENTAL
Intervention: Modified Shuttle Walk Test (MSWT) after 16 weeks of aerobic exercise intervention
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Modified Shuttle Walk Test (MSWT) in obese participants (N=128)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Change of measured and predicted V̇O2peak at follow-up
Number of subjects: 248
Study: 28333362

Group type: EXPERIMENTAL
Intervention: Budesonide multimatrix 9 mg
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study: 26600646

Group type: EXPERIMENTAL
Intervention: Structured Oral Examination (SOE)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Conventional Oral Examination (COE)
Number of subjects: 123
Study: 23924446

Group type: EXPERIMENTAL
Intervention: Immediate intravesical instillation of Pirarubicin (THP) 30 mg/50 ml within 24 hours post TUR, followed by regular instillations once a week for 8 weeks, then once a month for 1 year.
Number of subjects: 403

Group type: COMPARATOR
Intervention: Regular intravesical therapy only.
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Immediate intravesical instillation of Pirarubicin (THP) for low and intermediate-risk patients.
Number of subjects: 403

Group type: COMPARATOR
Intervention: Regular intravesical therapy only for low and intermediate-risk patients.
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Immediate intravesical instillation of Pirarubicin (THP) for high-risk patients.
Number of subjects: 403

Group type: COMPARATOR
Intervention: Regular intravesical therapy only for high-risk patients.
Number of subjects: 403
Study: 21922971

Group type: EXPERIMENTAL
Intervention: HemoStase
Number of subjects: 18

Group type: COMPARATOR
Intervention: FloSeal
Number of subjects: 18
Study: 19589565

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg followed by 200 mg every 12 hours for 10 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 53
Study: 16919541

Group type: COMPARATOR
Intervention: HI OA diet (fat, 40%; PA, 1.7%; OA, 31.4%)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: HI PA diet (fat, 40%; PA, 16.8%; OA, 16.4%)
Number of subjects: 19

Group type: COMPARATOR
Intervention: HI OA diet
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: HI PA diet
Number of subjects: 19
Study: 15585427

Group type: EXPERIMENTAL
Intervention: Peer education intervention (10-session training)
Number of subjects: 156
Study: 11385230

Group type: EXPERIMENTAL
Intervention: Griseofulvin 600 mg twice daily for 12 months
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily for 4 months
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Itraconazole pulse therapy (200 mg twice daily for 1 week with 3 weeks off between pulses)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg daily for 12 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg daily for 12 weeks
Number of subjects: 59
Study: 1443356

Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g intramuscular (i.m.) 1 hour preoperatively and a second dose 1 hour before catheter removal (Study 1)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Cefotaxime 1 g i.m. 1 hour preoperatively (Study 2)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g i.m. 1 hour before catheter removal (Study 2)
Number of subjects: 139
Study: 6399346

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no magnesium therapy)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium therapy (subgroup without heart failure)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (subgroup without heart failure)
Number of subjects: 76
Study: 29532734

Group type: EXPERIMENTAL
Intervention: sirukumab 50 mg every 4 weeks (q4w)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: sirukumab 100 mg every 2 weeks (q2w)
Number of subjects: 116

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: sirukumab 50 mg q4w
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: sirukumab 100 mg q2w
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: sirukumab combined groups
Number of subjects: 116
Study: 29436152

Group type: EXPERIMENTAL
Intervention: Wet hemodialysis session (immersion in 34 to 35°C bath)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dry hemodialysis session (standard hemodialysis)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Wet hemodialysis session
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dry hemodialysis session
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both sessions
Number of subjects: 10
Study: 27418379

Group type: EXPERIMENTAL
Intervention: Right unilateral ultrabrief pulse ECT combined with venlafaxine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 240
Study: 25124976

Group type: EXPERIMENTAL
Intervention: Sleep duration ≥10 hours
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Sleep duration 9–10 hours
Number of subjects: 143

Group type: COMPARATOR
Intervention: Sleep duration <9 hours
Number of subjects: 143
Study: 22773291

Group type: EXPERIMENTAL
Intervention: Physiotherapy group (PG) - 15 minutes of daily passive movements with gentle joint compression 5 days a week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study: 19965548

Group type: EXPERIMENTAL
Intervention: Cinacalcet plus low-dose calcitriol analogs (Cinacalcet-D)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Calcitriol analogs alone (Flex-D)
Number of subjects: 91
Study: 18664988

Group type: EXPERIMENTAL
Intervention: Penicillin/erythromycin therapy at school for positive throat cultures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group sought medical care from their regular provider
Number of subjects: 0
Study: 15882245

Group type: EXPERIMENTAL
Intervention: Moxifloxacin, tinidazole, and esomeprazole (Group MTE)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Moxifloxacin, amoxicillin, and esomeprazole (Group MAE)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard triple therapy with clarithromycin, amoxicillin, and esomeprazole (Group CAE)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard triple therapy with tinidazole (Group CTE)
Number of subjects: 320
Study: 12963604

Group type: EXPERIMENTAL
Intervention: Topical 0.3% ciprofloxacin solution or ointment
Number of subjects: 663
Study: 15321076

Group type: EXPERIMENTAL
Intervention: 0.3 mg subarachnoid diamorphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 mg epidural diamorphine
Number of subjects: 60
Study: 8675360

Group type: EXPERIMENTAL
Intervention: Group I (renal hypoperfusion)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Random urine urea excretion indices
Number of subjects: 27
Study: 1677616

Group type: EXPERIMENTAL
Intervention: Somatostatin (SST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no SST)
Number of subjects: 30
Study: 3893776

Group type: EXPERIMENTAL
Intervention: Chloroquine single dose of 10 mg/kg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Chloroquine full dose of 25 mg/kg
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: In vitro tests
Number of subjects: 109
Study: 29777297

Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT) performed at the end of procedure
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High verapamil administration (18%)
Number of subjects: 54
Study: 27119576

Group type: EXPERIMENTAL
Intervention: LCZ696 (400 mg, single dose) with omeprazole (40 mg q.d.)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: LCZ696 (400 mg, single dose) with metformin (1000 mg q.d.)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: LCZ696 (400 mg, single dose) with levonorgestrel-ethinyl estradiol (150/30 μg single dose)
Number of subjects: 79
Study: 24621518

Group type: EXPERIMENTAL
Intervention: Active VR condition
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Passive VR condition
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 69
Study: 25008950

Group type: EXPERIMENTAL
Intervention: Fish oil (4 g/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 21460332

Group type: EXPERIMENTAL
Intervention: Family-Provider Alliance Program
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 275
Study: 18094224

Group type: COMPARATOR
Intervention: Aspirin 325 mg alone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg alone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg followed by aspirin 325 mg 2 hours later
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Aspirin with NSAID (ibuprofen or naproxen)
Number of subjects: 28
Study: 16188909

Group type: EXPERIMENTAL
Intervention: FAT-adapt diet
Number of subjects: 7

Group type: COMPARATOR
Intervention: HCHO diet
Number of subjects: 7
Study: 14561562

Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention for mothers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (mothers not receiving the intervention)
Number of subjects: 0
Study: 10901564

Group type: EXPERIMENTAL
Intervention: Active management of labour (n = 320)
Number of subjects: 651

Group type: COMPARATOR
Intervention: Routine care (n = 331)
Number of subjects: 651
Study: 8835705

Group type: EXPERIMENTAL
Intervention: Brofaromine (150 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluvoxamine (Fluv)
Number of subjects: 30
Study: 1596968

Group type: EXPERIMENTAL
Intervention: 0.5 ml.kg‐1 bupivacaine 0.125% with 1:200,000 epinephrine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 1 ml.kg‐1 bupivacaine 0.125% with 1:200,000 epinephrine
Number of subjects: 80
Study: 6431130

Group type: EXPERIMENTAL
Intervention: Silicone elastomer (SE) catheters
Number of subjects: 75

Group type: COMPARATOR
Intervention: Polyurethane (PU) catheters
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both SE and PU catheters
Number of subjects: 75
Study: 31248843

Group type: EXPERIMENTAL
Intervention: Triple-drug group (cyclosporine, mycophenolate mofetil, and sirolimus)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Standard GVHD prophylaxis group (cyclosporine and mycophenolate mofetil)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Triple-drug group
Number of subjects: 167

Group type: COMPARATOR
Intervention: Standard GVHD prophylaxis group
Number of subjects: 167
Study: 29102441

Group type: EXPERIMENTAL
Intervention: Incobotulinum toxin A (Btx) - 100 UI in Flexor digitorum brevis
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Incobotulinum toxin A (Btx) - 100 UI in Flexor digitorum longus
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo in Flexor digitorum longus and Flexor digitorum brevis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo - 2 injections
Number of subjects: 45
Study: 26949119

Group type: EXPERIMENTAL
Intervention: Study eyes with manifest glaucoma
Number of subjects: 249

Group type: COMPARATOR
Intervention: Fellow eyes without visual field loss
Number of subjects: 249
Study: 24996030

Group type: EXPERIMENTAL
Intervention: Dipstick protein (DSP)
Number of subjects: 4211

Group type: EXPERIMENTAL
Intervention: Specific gravity (SG)
Number of subjects: 4211

Group type: EXPERIMENTAL
Intervention: Equation 1
Number of subjects: 4211

Group type: EXPERIMENTAL
Intervention: Equation 2
Number of subjects: 4211

Group type: EXPERIMENTAL
Intervention: Combination of DSP and SG with ALB
Number of subjects: 4211